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1. Introduction 
Hepatitis C virus (HCV) is the major cause of chronic liver disease worldwide. Up to 30% of 
infected individuals spontaneously resolve their acute infection, while others develop chronic 
hepatitis C and replicate the virus seemingly indefinitely, but the features of the host and virus 
that are responsible for this difference are not yet clear. The persistence of the virus in the liver 
can lead to cirrhosis and hepatocellular carcinoma. End-stage liver disease due to a chronic 
HCV infection is currently the number one reason for liver transplantation in many parts of 
the world. No prophylactic vaccine is presently available and the current antiviral therapy 
successfully suppresses HCV replication in fewer than 50% of patients with a chronic infection. 
Until recently, patients who had eliminated HCV spontaneously or after treatment were 
considered to be definitively cured. But reports of low HCV RNA concentrations in the 
plasma, peripheral blood mononuclear cells and livers of patients who had cleared HCV has 
led to uncertainty in both patients and physicians. This new form of HCV infection is called 
occult HCV infection. This chapter summarises the data presently available on occult HCV 
infections and discusses its significance and reality. 
1.1 HCV infection  
1.1.1 HCV virus 
Hepatitis C is a member of the Flaviviridae family. Its genome of approximately 9.5 kb is a 
positive RNA strand that encodes a large polyprotein of more than 3000 amino acid 
residues. The open reading frame is flanked by untranslated regions, the 5’ UTR and 3’ UTR. 
The 5’UTR region contains the internal ribosomal entry site (IRES). Processing and cleavage 
of the polyprotein yields structural and non-structural proteins (Figure 1). HCV has great 
genetic variability, with six genotypes and more than 70 subtypes (Simmonds et al., 2005).  
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Fig. 1. Organisation of the HCV genome. The region in gray encodes structural proteins and 
the white one non-structural proteins. 
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1.1.2 Natural history of HCV infection 
Patients infected with HCV virus first develop an acute disease that is usually 
asymptomatic. Diagnosis is confirmed by the detection of HCV genomic RNA in the plasma, 
which may also contain anti-HCV antibodies (Figure 2a). About 30% of infected patients 
spontaneously clear the virus, generally in the 3 months following clinical symptoms (Corey 
et al., 2006, Gerlach et al., 2003, Micallef et al., 2006) 
Unfortunately, 70% of infected patients develop a chronic HCV infection (Figure 2b). The 
plasma of these patients contains anti-HCV antibodies and HCV RNA. These patients can be 
divided into two groups. One group has normal liver enzyme activities, while the other has 
abnormal liver enzyme activities. Thus, 7 - 53% of patients with a chronic HCV infection 
have normal alanine aminotransferase activities (Alter, 2005, Mathurin et al., 1998, Persico et 
al., 2000). Hepatic lesions are moderate, but liver biopsies have shown that 90% of patients 
suffering from chronic hepatitis have lesions (Marcellin et al., 1997b). Analysis of liver 
biopsies indicates that most patients with a chronic HCV infection have elevated liver 
enzymes and moderate to severe lesions. About 25% of them develop liver cirrhosis, and 
this results in hepatocellular carcinoma in 2% of them (Alberti et al., 1999). Liver 
transplantation is the only treatment available to these patients. 
 
(a) 
 
(b) 
 
Fig. 2. Natural history of acute (a) and chronic (b) HCV infections. 
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The natural history of an HCV infection can be modified by anti-HCV therapy. The current 
antiviral therapy for a chronic HCV infection is pegylated interferon plus ribavirin. It is 
recommended for patients with a liver fibrosis score of F2 or more. A sustained virological 
response, defined as undetectable HCV RNA in the serum 6 months after the end of 
treatment, is achieved in 40-70% of treated patients, depending on the HCV genotype. 
Patients infected with HCV genotype 1 have a lower sustained virological response (40%) 
than patients infected with HCV genotypes 2 or 3 (80%). New antiviral therapies targeting 
directly the HCV genome, anti-protease and anti-polymerase, will improve the sustained 
virological rate in HCV genotype 1 infected patients (Legrand-Abravanel et al., 2010, 
McHutchison et al., 2009). Recently, one genetic marker, interleukin 28B, was identified as a 
factor influencing the natural history of HCV infection and the treatment success of patients 
chronically infected: patients with a CC genotype clear the virus more easily (Ge et al., 2009, 
Thomas et al., 2009).  
1.1.3 HCV infection in particular populations 
The progression of HCV infections in patients with impaired immune systems differs from 
that in immunocompetent patients. We will focus on patients with end-stage renal disease 
and patients with an HIV coinfection. 
The blood of patients undergoing regular dialysis is much more likely to contain anti-HCV 
antibodies (7 to 40%)  than that of the general population (Rahnavardi et al., 2008), although 
the percentage has been lower in the past few years because of improved prevention 
measures, like using gloves, single-use material, and the isolation of HCV-infected people in 
dialysis units. But it still occurs in French hemodialysis units and requires appropriate 
management, even though the prevalence of HCV infection has decreased by 7.7% (Saune et 
al., 2010). It is difficult to evaluate the natural history of HCV in hemodialysis patients 
because the exact date of contamination is often unknown and the infection can be silent for 
several years. The liver enzyme activities cannot be used to predict the development of 
fibrosis in these patients; they can have hepatic lesions with normal liver enzyme activities 
(Furusyo et al., 2000, Martin et al., 2000). HCV infection is a significant cause of morbidity 
and mortality in patients with end-stage liver disease, and particularly in renal transplanted 
recipients. Death is generally due to liver dysfunction and loss of the renal graft. HCV 
infection has been linked to shorter allograft survival and more acute rejection episodes and 
virus-related glomerulonephritis (Pereira et al., 1998). Interferon-based treatment after renal 
transplantation is associated with graft loss and so is not recommended. It has been 
recommended that all kidney-transplant candidates be treated with alpha-interferon 
because of the relatively high rate of sustained virological response in HCV-positive dialysis 
patients given anti-HCV therapy (Izopet et al., 1997, Rostaing et al., 1998). 
About 30% of patients infected with HIV are also infected with HCV.  HCV infections have 
become the main cause of morbidity and mortality due to faster development of cirrhosis 
and hepatocellular carcinoma. These patients are less likely to spontaneously clear their 
HCV infection and their HCV virus load is often higher than average (Thomas et al., 2000). 
The virus load is especially increased in patients with low CD4+ T cells counts, probably 
due to loss of immune control. The rate of sustained virological response is lower in these 
patients than in those infected with HCV alone. Only 14-38% of patients infected with HCV 
genotypes 1 or 4 and HIV achieve a sustained virological response, while  44-73% of patients 
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infected with HIV and HCV genotype 2 or 3 do so (Carrat et al., 2004, Chung et al., 2004, 
Laguno et al., 2004, Torriani et al., 2004). 
1.2 HCV tropism 
HCV mainly replicates in the liver but there are other extra-hepatic replication sites.  
1.2.1 The liver 
The liver is the major replication site and contains high concentrations of HCV RNA (about 
108-1011 copies per g tissue) (Sugano et al., 1995). HCV particles, free or associated with 
serum apolipoproteins, interact with multiple cell surface proteins on hepatocytes (Boonstra 
et al., 2009). The initial interaction involves glycosaminoglycans (GAGs) and lipoprotein 
receptors (LDLR), as well as scavenger receptor class B type I (SR-BI), followed by the 
recruitment of tetraspanin, CD81, and the later use of the tight junction proteins claudin-1 
and occludin (OCLN). 
In situ hybridization studies found HCV RNA in 5 to 50% of the liver cells of patients 
chronically infected with HCV genotype 1 (Pal et al., 2006). The proportion of hepatic cells 
with detectable negative strand HCV RNA (a marker of HCV replication) was closely 
correlated with the liver enzyme activities and histological changes. Histological damages 
observed in HCV infection are the results of productive infection of some liver cells.  
1.2.2 Extra-hepatic sites 
HCV RNA has been detected in the peripheral blood mononuclear cells of chronically 
infected patients (Blackard et al., 2005, Laskus et al., 2000, Lerat et al., 1996, Lerat et al., 1998, 
Muller et al., 1993, Navas et al., 1998), in the central nervous system (Forton et al., 2004, 
Morsica et al., 1997), and other tissues like pancreas, thyroid, spleen (Laskus et al., 1998), 
seminal fluid (Bourlet et al., 2002, Pasquier et al., 2000). Negative strand HCV RNA was also 
detected, suggesting HCV replication. 
HCV compartmentalization has been described in lymphocytes B cells and dendritic cells 
(Ducoulombier et al., 2004). The HVR1-E2 sequences found in cells were different from 
those found in the plasma. Some of the 109 patients tested had very different strains in 
their peripheral blood mononuclear cells that was undetectable in their plasma (Roque-
Afonso et al., 2005). The sequences found in the peripheral blood mononuclear cells of 9 
patients were different enough to be classified as another genotype, distinct from the 
sequences found in the plasma. These strains could have been acquired during co-
infection or super-infection. A significant proportion of patients with hepatitis C are 
infected with two or more HCV variants with distinct IRES sequences and distinct cellular 
tropism (Di Liberto et al., 2006, Durand et al., 2010). HCV compartmentalization was an 
independent predictor of treatment response in this study. They also found a correlation 
between the cellular tropism of HCV variants for liver or B cells in vivo and the 
translational efficiency of their IRES. The IRES of the B cell-specific strains all had a 
common activity profile and were consistently less efficient than paired plasma IRES in 
hepatocytes. These findings suggest that HCV replicates extra-hepatically in chronically 
infected patients. As HCV genotype 1 was more frequently detected than HCV genotypes 
2 or 3, this genotype could be better adapted to mononuclear cells (Lerat et al., 1998). 
Some patients developed a cellular T cells response against a virus whose genotype 
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differed from that of the one detected in plasma (Sugimoto et al., 2005). Patients with 
HCV compartmentalization in mononuclear cells could develop a stronger immune 
response, so facilitating virus elimination.  
2. Virological tools 
The diagnosis of an HCV infection (acute and/or chronic) is based on the detection of 
serological and molecular markers in serum and plasma. They are also used to initiate 
treatment and to monitor treatment efficacy. 
2.1 Serological assays 
Anti-HCV antibodies in the blood plasma or serum are detected using third-generation 
enzyme immunoassays, which are specific for antibodies against various HCV epitopes. 
Recombinant antigens are used to capture circulating anti-HCV antibodies. Third-generation 
enzyme immunoassays are better than 99% specific for anti-HCV antibodies. Their sensitivity 
is more difficult to determine, given the lack of a reference (gold standard) method, but it is 
excellent in HCV-infected immunocompetent patients. Detection systems for serum HCV 
antibodies are insensitive in the acute phase because of long serological window. 
Immunoassays combining detection of anti-HCV antibodies and HCV antigen reduce the 
serological window of over 25 days (Laperche et al., 2005). Recently, quantitative 
immunoassays detecting HCV core antigen were developed. The HCV Ag level correlates the 
HCV RNA concentration. It can reduce the serological window of over 35 days and is highly 
specific to detect acute HCV infection in haemodialysis patients (Miedouge et al., 2010).  
2.2 HCV RNA detection and quantification 
The presence of HCV RNA in serum or plasma is first used to diagnose an HCV infection. 
The presence of HCV RNA alone, with no anti-HCV antibodies, strongly indicates an acute 
HCV infection, which must then be confirmed by seroconversion (the appearance of anti-
HCV antibodies) a few days or weeks later. Acutely infected patients can also have both 
HCV RNA and anti-HCV antibodies at the time of diagnosis. It is difficult in this case to 
distinguish acute hepatitis C from an acute exacerbation of chronic hepatitis C. A patient 
with clinical or biological signs of chronic liver disease will have chronic hepatitis C if both 
the anti-HCV antibodies and the HCV RNA are present for at least 6 months. Description of 
HCV replication in the absence of anti-HCV antibodies is rare with the current enzyme 
immunoassays, but occurs in profoundly immunodepressed patients, hemodialysis patients 
or agammaglobulinemic subjects.  
The presence of HCV RNA is checked regularly during anti-HCV treatment and treatment is 
stopped or continues depending on the result. The end-of-treatment and sustained 
virological responses should be assessed with a sensitive HCV RNA assay, with a lower 
detection limit of 50 IU/mL or less, according to Consensus Conference recommendations 
(Anonymous, 2002). The detection of HCV RNA at the end of therapy is highly predictive of 
a post-treatment relapse, whereas the absence of HCV RNA at the end of treatment indicates 
a virological response. Patients showing a virological response must be retested for HCV 
RNA with a sensitive method 24 weeks later to identify a sustained virological response, the 
endpoint of therapy. 
Both qualitative and quantitative assays can be used to detect HCV RNA. Qualitative 
assays use the principle of target amplification with a “classic” polymerase chain reaction 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 
 
312 
(PCR), “real-time” PCR or “transcription-mediated amplification” (TMA). Quantitative 
assays are based on target amplification techniques (competitive PCR or real-time PCR) or 
signal amplification techniques (branched DNA (bDNA) assays). The commercial assays 
for HCV RNA are summarized in Table 1. Their ranges of quantification vary 
considerably.  
 
Quantification range 
IU/mL 
 
Supplier
Detection 
limit IU/mL
Lower limit Upper  limit 
Qualitative assays     
TMA-based assay Versant Siemens 5-10 NA NA 
Cobas Amplicor v2.0 Roche 50 NA NA 
APTIMA® HCV RNA Genprobe 5.3 NA NA 
Quantitative assays     
LCx®HCV RNA Quantitative Assay Abbott 10 12 100 000 000 
Cobas Ampliprep/Cobas TaqMan Roche 10 43 69 000 000 
Cobas Amplicor Monitor v2.0 Roche 600 600 500 000 
ARN HCV versant 3.0 Siemens 615 615 7 700 000 
Table 1. Detection limits and quantification ranges of commercial techniques for detecting 
HCV RNA. NA = not applicable 
2.3 HCV genotyping 
The HCV genotype is routinely determined before treating because the treatment duration, 
ribavirin dose and virological monitoring procedures depend on the HCV genotype. 
The reference method for HCV genotyping is direct sequencing of the NS5B or E1 regions of 
the HCV genome by means of “in-house” techniques, followed by sequence alignment with 
prototype sequences and phylogenetic analysis (Sandres-Saune et al., 2003, Simmonds et al., 
2005). In clinical practice, HCV genotype can be determined by various commercial kits that 
use direct sequence analysis of the 5’UTR region (Halfon et al., 2001) or reverse 
hybridization analysis with genotype-specific probes located in the 5’UTR region (Verbeeck 
et al., 2008). Unfortunately, analysis of this region tends to misclassify a significant number 
of HCV subtypes. For example, 20-30% of subtype 1a are not correctly identified (Chen and 
Weck, 2002). Real-time PCR methods and DNA biochip methods are now available 
(Gryadunov et al., 2010, Mao et al., 2010, Martro et al., 2008, Nakatani et al., 2010, Park et al., 
2009, Verbeeck et al., 2008). Methods based on analysis of the NS5B region are better for 
discriminating between HCV subtypes (Table 2) (Gryadunov et al., 2010, Sandres-Saune et 
al., 2003). 
Analysis of HCV heterogeneity can be used to determine the source of contamination in 
cases of nosocomial transmission. The tools should be based on regions of the HCV genome 
that are variable enough to discriminate between HCV subtypes and even different clusters 
within a subtype. The best are the NS5B and hypervariable 1 (HVR1)-E2 regions (Figure 1). 
These are different enough to clearly indicate whether the viruses circulating in different 
people have a common source (Bracho et al., 2005, Izopet et al., 1999). These regions can also 
be analysed to determine whether a patient who suffers a late relapse does so because of 
reactivation of the former virus or because of a new infection with a virus belonging to the 
same subtype.  
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Assay HCV region Genotype identification Subtype identification 
Line Probe 
Assay 
5’NC (I) 
5’NC+core (II) 
1-6 (mis-typing of G6) 
1-6 (better idenfication of G6) 
Mis-subtyping 
Subtype 1a/1b  
Sequencing NS5B or core/E1 1-6 Reference method 
 5’NC 1-6 (false idenfication of G6) Mis-subtyping 
Real time PCR 5’NC or NS5B 1-6 Only subtypes 1a, 1b, 
2a, 2b, 2c 
DNA biochip 5’NC 1-6 Only subtypes 1a, 1b 
 NS5B 1-6 More than 30 subtypes 
Table 2. Performance of HCV genotyping methods. 
3. Definition of an occult HCV infection 
The clinical resolution of a hepatitis C infection, either spontaneous or therapy-induced, has 
conventionally been deemed to reflect the complete eradication of HCV. However, the past 
5 years have seen an emergence of several studies documenting the presence of HCV RNA 
in the liver or peripheral blood mononuclear cells of patients whose serum samples tested 
negative for HCV RNA by conventional PCR assays, with or without the presence of anti-
HCV antibodies. This defined a new form of HCV infection, called occult HCV infection. 
Occult HCV infections were described using highly sensitive nucleic acid amplification 
assays with a sensitivity < 3 IU/mL. There are two forms of occult HCV infections: 
cryptogenic and secondary (Table 3). 
 
Description 
Cryptogenic occult HCV 
infection 
Secondary occult 
HCV infection 
HCV RNA detection   
  Plasma (conventional PCR assay) * - - 
  Plasma (ultrasentive PCR assay ) ** +/- +/- 
  Peripheral blood mononuclear cells +/- +/- 
  Liver biospy + +/- 
Anti-HCV antibodies - + 
Elevated liver enzymes yes no 
* Detection limit 50-600 UI/mL, ** detection limit ≤ 3 IU/mL 
Table 3. Markers of occult HCV infection.  
3.1 Cryptogenic occult HCV infection 
Occult HCV infections are termed cryptogenic if the patient has (1) no anti-HCV antibodies 
and (2) elevated liver enzyme activities (Table 3).  
Castillo et al (Castillo et al., 2004) first described “occult HCV infections” in patients with 
hepatic disorders of unknown origin; they appeared to have no anti-HCV antibodies or HCV 
RNA by conventional techniques. All other known causes of liver disease were excluded 
(viruses, autoimmune hepatitis, alcoholism, drugs, metabolic and genetic liver disorders). 
They used very sensitive PCR methods to detect genomic HCV RNA in the livers of 57 of the 
100 patients tested. This rate of positive sample was unexpectedly high. Negative strand HCV 
RNA was detected in 84% of these 57 patients by in situ hybridization. The peripheral blood 
mononuclear cells from 70% of these patients were also positive for HCV RNA. 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 
 
314 
Another study detected the HCV RNA genome in the hepatocytes of 27 of 31 patients, none 
of whom had markers of HCV infection or any abnormal liver function test (Idrees et al., 
2010). Both positive and negative strand HCV RNA were found in the livers of 8 (25.8%) 
patients, suggesting ongoing virus replication in hepatocytes. The main studies describing 
cryptogenic occult HCV infections are shown in Table 4. 
3.2 Secondary occult HCV infection  
Occult HCV infections have also been described in patients (1) with anti-HCV antibodies 
and (2) with normal liver enzyme activities who had cleared their HCV infections, either 
spontaneously or after treatment. This defined cases of secondary occult HCV infection 
(Table 3).  
The persistence of HCV after hepatitis C had been resolved spontaneously or by treatment was 
first described in 16 patients (Pham et al., 2004). A very sensitive method (detection limit: 10 
copies/mL) revealed HCV RNA in the plasma of 88% of them and in the peripheral blood 
mononuclear cells of 81% of patients; it was also found in 86% of the monocytes tested. Similar 
results were obtained in 17 patients whose hepatitis C had been resolved by treatment: 24% 
had HCV RNA in their serum, 53% in peripheral blood mononuclear cells, 41% in 
lymphocytes and 65% in macrophages (Radkowski et al., 2005a). Castillo et al detected 
positive and negative-strand HCV RNA in liver biopsy specimens and cells of 20 sustained 
responders (Castillo et al., 2006). Positive-strand HCV RNA was detected in 95% of liver 
biopsy specimens and negative-strand HCV RNA (the replication intermediate) was found in 
79% of liver biopsy samples that had positive-strand HCV RNA. Thirteen (65%) samples of 
peripheral blood mononuclear cells had positive-strand HCV RNA; and 12 of these (92%) also 
had negative-strand HCV RNA. This suggested that virus replication was taking place in the 
liver of these patients, which could explain the persistence of intrahepatic HCV years after 
successful antiviral therapy. In another study, HCV RNA was detected in the serum of 54% of 
patients who had spontaneously cleared their HCV infection; it was also found in the 
peripheral blood mononuclear cells of 50 to 64% of them (Carreno et al., 2006, Radkowski et 
al., 2005b). The main studies describing secondary occult HCV infections are shown in Table 4. 
3.3 Diagnosis of occult HCV infections 
As the first definition of an occult HCV infection was based on detecting HCV RNA in 
hepatocytes (Castillo et al., 2004), the presence of HCV RNA in the liver is the reference 
method. However, liver biopsies are not readily available and the newly available non-
invasive methods for evaluating fibrosis will make biopsy-based methods less common. 
Carreño et al (Carreno et al., 2004) showed that HCV RNA can be detected in the peripheral 
blood mononuclear cells of 70% of patients with an occult HCV infection. So an alternative 
for diagnosing an occult HCV infection could be to look for HCV RNA in peripheral blood 
mononuclear cells. Ultrasensitive PCR assay can also detect HCV RNA in the plasma or 
serum, although it is undetectable by conventional PCR assay. Thus, HCV RNA 
concentrations of 60 - 160 copies/mL can be detected in the plasma of patients with an 
occult HCV infection using an ultrasensitive PCR assay (Bartolome et al., 2007)  
All the groups that have described occult HCV infections used different methods to increase 
the chance of detecting low concentrations of HCV RNA (Pham et al., 2010).  
- The first were highly sensitive molecular biological methods with a detection limit of 
about 3 IU/mL. They were based on nested PCR after reverse transcription targeting 
the 5’UTR region of the HCV genome. Amplification was often improved by nucleic 
acid hybridization (Southern blotting).  
www.intechopen.com
 
Occult Hepatitis C Virus Infection: Where are We Now? 
 
315 
- The second method consisted of stimulating peripheral blood mononuclear cells ex vivo 
by culturing them with mitogens (interleukin-2 and phytohemaglutinin). This increased 
the detection of the HCV genome in cells apparently not infected with HCV (Pham et 
al., 2004, Pham et al., 2005). HCV RNA was detected in the peripheral blood 
mononuclear cells of about 30% of patients who had cleared HCV, but this percentage 
can increase up to 75% if the mononuclear cells are cultured with mitogens. 
- The third method used an unconventional amount of plasma and number of cells, with 
plasma volumes of 1 - 4 mL and large numbers of cells (5x105 - 4x106 cells) (Bartolome et 
al., 2007, Castillo et al., 2009, Radkowski et al., 2005a). This improved the diagnosis of 
an occult HCV infection by 10-15%.  
- Finally, it is also important to repeat tests on successive samples of plasma and 
peripheral blood mononuclear cells because HCV RNA detection is rarely permanent. 
Repeated testing leads to the detection of occult HCV infections in 100% of cases (Pham 
et al., 2004, Pham et al., 2008, Radkowski et al., 2005a).  
Unfortunately, while these techniques seem to be necessary for detecting an occult HCV 
infection, they are not really suitable for clinical diagnosis. 
 
Negative HCV RNA  HCV RNA detection (ultrasensitive PCR assay) 
Study 
Patient 
number 
Anti HCV 
antibodies  
Hepatic 
cytolysis 
Liver biopsy 
Peripheral blood 
mononuclear cells 
Plasma  
HCV 
genotype 
(Castillo et al., 2004)* 100 - Yes 57/100  
(57%) 
40/57  
(70%) 
NA 1b 
(Bartolome et al., 2007)* 106 - Yes 106/106  
(100%) 
69/106  
(65%) 
62/106  
(58%) 
1b 
(Barril et al., 2008)* 109 - Yes NA 49/109  
(45%) 
NA 1b 
(Idrees et al., 2010) 31 - Yes 23/31 
 (74%) 
NA NA 3a, 3b, 1a 
(Pham et al., 2004)*† 16 + No NA 13/16  
(81%) 
15/17  
(88%) 
1a, 1b, 2a 
(Radkowski et al., 2005a)*† 17 + No 3/11  
(27%) 
9/17 
 (53%) 
4/17  
(24%) 
1a, 1b, 2a, 3a 
(Radkowski et al., 2005b)*† 11 + No NA 7/11  
(64%) 
6/11  
(54%) 
1a, 1b 
(Carreno et al., 2006)* 12 + No 10/12  
(83%) 
6/12  
(50%) 
NA 1b 
(Castillo et al., 2006) 20 + No 19/20  
(95%) 
13/20  
(65%) 
NA 1b, 2, 3 
(Gallegos-Orozco et al., 2008)† 25 + No NA 5/25  
(20%) 
0/25  
(0%) 
1, 2 
 
* Southern blot detection, † stimulation of cells in culture with mitogens, NA= not applicable 
Table 4. Detection of HCV genomic RNA in different compartments in studies on occult 
HCV infections. 
4. Clinical significance of occult HCV infections 
To date, only one study had investigated the clinical characteristics of an occult HCV 
infection (Pardo et al., 2007). Two groups of patients were compared. One group of 68 
patients had a cryptogenic occult HCV infection while the second group of 69 patients had a 
chronic HCV infection. The groups were matched for age, gender, body mass index and the 
estimated duration of abnormal liver function tests. Patients with an occult HCV infection 
had significantly higher plasma cholesterol and triglycerides that patient with a chronic 
HCV infection. But the activities of their alanine aminotransferases and gamma glutamyl 
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transpeptidases were lower. Liver biopsies showed that patients with chronic HCV 
infections had higher necro-inflammatory activities (96%) and fibrosis scores (75%) than did 
patients with an occult HCV infection (31% and 15%). However, the two groups had similar 
proportions of patients with cirrhosis or hepatic steatosis. Patients with an occult HCV 
infection had fewer HCV-infected hepatocytes (5.3%) than patients with a chronic HCV 
infection (10.1%). Therefore, an occult HCV infection results in fewer hepatic lesions than a 
chronic HCV infection. This could be due to the slow replication of HCV RNA observed in 
occult HCV infections.  
Another study evaluated the efficacy of anti-HCV treatment in occult HCV infections (Pardo 
et al., 2006). They treated 10 patients with a cryptogenic HCV infection with pegylated 
interferon and ribavirin for twenty-four weeks. These patients had HCV RNA in their livers 
and peripheral blood mononuclear cells, and all had elevated liver enzymes activities. At 
treatment withdrawal, eight patients had normal liver enzyme activities and the peripheral 
blood mononuclear cells of eight tested negative for HCV RNA. Twenty-four weeks after 
treatment withdrawal, six patients still had normal liver enzymes and seven had peripheral 
blood mononuclear cells that were negative for HCV RNA. Two biopsies were taken from 
five patients, one before and one after treatment. HCV RNA was found in the second liver 
biopsy of all five patients. However, the HCV RNA concentrations in the liver biopsy taken 
after treatment were lower than in the pre-treatment samples and the number of infected 
hepatocytes was also lower (2.2%) after treatment than before (3.5%). The necro-
inflammatory activity and fibrosis scores had also decreased in three of the five patients. 
Thus treating patients with a cryptogenic occult HCV infection can improve their liver 
histology. 
5. HCV infectivity in occult HCV infection 
The crucial questions are, first, whether detecting HCV RNA fragments, even from the 
negative strand, should be interpreted as ongoing virus replication, or as molecular residues 
of a resolved HCV infection and, second, whether patients with low concentrations of HCV 
RNA can transmit an infectious virus. The presence of negative stranded HCV RNA in 
peripheral blood mononuclear cells and in the liver of more than 50% of patients with occult 
HCV infection indicated virus replication. The virus detected in the plasma of patients with 
an occult HCV infection was identified in particles with densities of 1.03-1.04 to 1.08-1.19 
g/mL (Bartolome et al., 2007). These densities are similar to those of the HCV viruses found 
in chronically infected patients. 
Cultures of lymphoid cells established by treating peripheral blood mononuclear cells from 
healthy individuals with a T cell inducing mitogen ex vivo are susceptible to wild-type HCV 
and capable of supporting its complete replication cycle (MacParland et al., 2006). This 
system was used to investigate the infectious capacity of low concentrations of HCV RNA, 
derive from the blood plasma or from the supernatant of peripheral blood mononuclear 
cells of patients with a sustained virological response. The residual virus in the plasma of 
patients with an occult HCV infection can be infectious in vitro (MacParland et al., 2009). The 
HCV carried by three of the nine individuals studied produced an infection in vitro. Thus, 
the HCV RNA detected in the plasma of patients with an occult HCV infection was found to 
be infectious, however the number of experiments was small. If these data are confirmed, an 
occult HCV infection could facilitate the clinical reactivation of an HCV infection, especially 
in patients with a damaged immune system. The public health impact and significance for 
blood and organ donation of such a situation could be very serious. 
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However, the infection of peripheral blood mononuclear cells is surprising because they do 
not have some of the membrane receptors that are essential for HCV entry into hepatocytes. 
They have no SR-BI, claudin-1 or occludin receptors. Moreover, cell-culture produce HCV 
(HCVcc) could not replicate in peripheral blood mononuclear cells, whatever the cells are 
(Marukian et al., 2008).  
6. Immunology in occult HCV infections 
Adaptive cellular immune response mechanisms, especially T cell responses, are believed to 
play a key role in the recovery from an HCV infection as well as in chronic hepatitis C.  
Proliferative CD4+ and CD8+ T cell responses are more efficient in patients with an occult 
HCV infection than in patients with a chronic HCV infection. 
6.1 Humoral immune response 
Patients with a classical HCV infection develop specific anti-HCV antibodies against virus 
structural and non-structural proteins. The antibodies appear late after the HCV infection 
and can never be detected in some cases. HCV can easily evade control by the humoral 
immune system. The titer of anti-HCV antibodies decrease rapidly in recovered chronically 
HCV infected patients given interferon-based therapy (Maylin et al., 2009, Toyoda et al., 
2005) and can sometimes completely disappear about two decades after HCV recovery 
(Takaki et al., 2000). Loss of anti-HCV antibodies can be observed in 6 to 20% of 
immunocompetent patients (Kondili et al., 2002, Lefrere et al., 2004) and in hemodialysis 
and immunocompromised patients. Patients with a cryptogenic occult HCV infection could 
be patients who have lost their anti-HCV antibodies.  
An immunoenzymatic test targeting the core protein has been developed recently. It detects 
immunoglobulin G that targets an immunodominant epitope of the HCV capsid (amino 
acids 5 to 19) that is not detected by other tests. Anti-HCV core antibodies are detected in 
98.6% of chronically infected individuals. This test was used to examine the plasma of 145 
serological silent patients with a cryptogenic occult HCV infection; 45 of them tested 
positive for anti-HCV antibodies (Quiroga et al., 2009). This IgG anti-HCV core test 
identifies occult HCV infections in seronegative, non-viremic patients and may be useful for 
tracking infections in patients who test negative for anti-HCV antibodies. 
6.2 Cellular immune response 
Specific T-cell responses alone can control an HCV infection even without an efficient 
humoral immune response (Post et al., 2004). The cellular immune response can still be 
detected decades after recovery from a chronic or acute HCV infection (Semmo et al., 2005, 
Takaki et al., 2000).  The authors found that HCV-specific T helper cells and cytotoxic T-cell 
responses with an interferon-gamma phenotype persisted. HCV specific T-CD8+ cells have 
been detected in people who were not infected with HCV but were in continuous contact 
with chronically infected HCV patients (Scognamiglio et al., 1999). This suggests that an 
immune response can be constructed in response to a subclinical HCV infection. The 
persistence of a T-specific immune response could be the result of low concentrations of 
HCV RNA that are undetectable by present techniques. One study compared the cellular 
immune responses of 50 patients with a cryptogenic occult HCV infection, 141 patients with 
a chronic HCV infection and 21 patients with cryptogenic liver pathology (Quiroga et al., 
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2004). Fifty-two per cent of the patients with a cryptogenic occult HCV infection had a 
specific proliferative CD4+ T cell response to HCV. Significantly fewer patients with a 
chronic HCV infection (26%) had this CD4+ T cell response. The specific HCV T cells 
detected targeted non-structural proteins and produced gamma interferon. The specific 
proliferative CD8+ T anti-HCV response in patients with an occult HCV infection was also 
stronger than in chronically infected patients. The cellular immune response may be more 
efficient in patients with an occult HCV infection, but it is not strong enough to definitively 
eliminate the virus. The same team demonstrated that HCV-specific CD4+ and CD8+ 
proliferative responses were observed more frequently in patients who have spontaneously 
eliminated the virus than in those whose chronic infection was eliminated by treatment 
(Quiroga et al., 2006). 
The peripheral blood mononuclear cells like dendritic cells, monocytes, CD4+ and CD8+ T 
cells, and B cells of chronically infected patients can contain HCV virus particles. Pham et al 
found that the same cells were infected in patients with an occult HCV infection (Pham et 
al., 2008). However, the cytokine profiles differed depending on the type of infection (Pham 
et al., 2009). The peripheral blood mononuclear cells of patients with occult HCV infection 
produced more alpha-interferon, gamma interferon and tumor necrosis factor alpha than 
did those of patients with a chronic HCV infection. But transcription of the interleukin 10 
gene was lower in patients with an occult HCV infection. Clearly, the impact of an occult 
HCV infection on the immunological function of T cells seems to be different from that of a 
chronic HCV infection, and needs further investigation.  
7. Populations at risk of an occult HCV infection: hemodialysis and 
immunocompromised patients 
Genomic HCV RNA was very recently found in the peripheral mononuclear cells of 45% of 
a group of serum HCV antibody-negative/HCV RNA-negative hemodialysis patients with 
elevated liver enzyme activities (Barril et al., 2008). This could have a big impact on the 
management of hemodialysis patients in dialysis units. But these results should be 
interpreted with caution for several reasons (Kamar et al., 2009). First, they found that the 
liver enzyme activities of patients with an occult HCV infection were abnormal, whereas the 
liver enzyme activities of dialysis patients with a chronic active HCV infection were often 
within the normal range. Second, they reported a very high percentage of deaths (39%) 
during the short follow-up, but these deaths were not due to HCV liver disease. This 
suggests that there was another underlying disease, other than an HCV infection, that was 
responsible for the increased liver enzyme activities. Third, seven of these hemodialysis 
patients had received a kidney transplant, but their serum remained HCV RNA-negative 
after kidney transplantation. There is usually a significant increase in the serum HCV RNA 
concentration of HCV RNA-positive patients after transplantation because of the loss of 
immune control under immunosuppression (Gane et al., 1996, Pereira and Levey, 1997, 
Rostaing et al., 2000). Hence, it is surprising that no HCV RNA was detected in the serum of 
the seven kidney transplant patients who had an occult HCV infection before 
transplantation.  
HCV reactivation should readily occur in immunocompromised patients if HCV really does 
persist, due to the loss of immune control caused by the regimen of immunosuppressive 
drugs. We monitored 26 kidney-transplant patients for 10.5 years (range 2–16) after they had 
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eliminated their HCV while on hemodialysis. We search for the presence of HCV RNA in 
liver biopsies, blood plasma and peripheral blood mononuclear cells (Nicot et al., 2010). The 
peripheral blood mononuclear cells were stimulated with a mitogen in culture to increase 
the chance of detecting low concentrations of HCV RNA. We repeated the tests using a very 
sensitive RT-PCR assay with Southern blotting detection (detection limit, 2 IU/ml). We 
found no residual HCV RNA in samples tested at the last follow-up. Half the patients were 
given rabbit antithymocyte globulins and anti-CD3 monoclonal antibodies during induction 
therapy and for biopsy-proven acute rejection, twenty patients were given mycophenolic 
acid. These drugs increase HCV viremia in HCV-infected patients (Nelson et al., 2001, 
Rostaing et al., 2000, Zekry et al., 2004), but none of the kidney-transplant patients tested 
had any detectable HCV RNA in their plasma. And none of them developed any HCV-
related glomerulopathy or liver disease during this long follow-up. No patients who 
underwent a post-treatment liver biopsy showed any deterioration of their liver histology. 
The fact that formerly HCV-infected immunocompromised patients did not suffer a relapse 
suggests the complete eradication of HCV after its elimination while on dialysis.  
8. Occult hepatitis C virus infection: the controversy 
The data that are presently available on occult HCV infections are conflicting. Studies 
carried out by three different groups are in favor of occult HCV infection (Carreno et al., 
2006, Castillo et al., 2004, Castillo et al., 2005, Castillo et al., 2006, Radkowski et al., 2005a, 
Radkowski et al., 2005b), while those of many others support the recovery of an HCV 
infection (Bernardin et al., 2008, George et al., 2009, Maylin et al., 2008, Maylin et al., 2009, 
Nicot et al., 2010, Swain et al., 2010, Wiegand et al., 2004). Several arguments are in favor of 
the absence of persistent HCV RNA. HCV is an RNA virus that has no latent stage in its 
replication cycle and its genome cannot persist as DNA, unlike viruses like HIV, HBV and 
herpes viruses. It is therefore unclear how low concentrations of HCV can persist.  
8.1 Relapse rate is low in patients successfully treated 
Relapse rate is extremely low. However, for patients who experienced late relapse, it is not 
clear whether they suffer a true relapse or are re-infected. 
8.1.1 Results of long-term follow-up studies 
Long-term follow-up studies have indicated that patients achieving a sustained virological 
response are at little risk of a late virologic relapse. One conducted on more than 1300 
patients given peginterferon alfa-2a, alone or in combination with ribavirin assessed 
whether a sustained virological response was synonymous with HCV elimination (Swain et 
al., 2010). It included HCV infected patients alone or co-infected with HIV, with elevated or 
persistently normal liver enzyme activities. They found that 99.1% of the patients who 
achieved a sustained virological response after treatment still had undetectable HCV RNA 
in their serum after a mean follow-up of 3.9 years (range, 0.8 –7.1 years). Another large 
review of more than 4000 patients derived from studies conducted between 1994 and 2008 
concluded that only 3% of sustained virological responders showed evidence of a late 
recurrence of HCV RNA (between 6 months and 7 years) (Welker and Zeuzem, 2009). 
Immunocompetent and immunocompromised patients (liver or renal transplanted patients) 
treated with interferon or pegylated interferon alone or associated with ribavirin were 
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included. Smaller studies reported similar findings: serum HCV RNA remained 
undetectable in 92% to 100% of patients who achieved a sustained virological response after 
2 to 13 years of follow-up (Desmond et al., 2006, Formann et al., 2006, Marcellin et al., 1997a, 
Veldt et al., 2004).  
The description of occult HCV infections was followed by several large cohort studies 
looking for trace amounts of HCV in the plasma, peripheral blood mononuclear cells 
and/or liver of various populations. HCV RNA was not detected in the plasma or 
peripheral blood mononuclear cells of 156 of 344 successfully treated immunocompetent 
patients followed-up for a median of 3.3 years. While none of these patients suffered a 
virologic relapse, HCV RNA was detected in 2 of the 114 liver biopsies tested (Maylin et 
al., 2008). A study on 69 aviremic blood donors found no detectable HCV RNA in their 
peripheral blood mononuclear cells (Bernardin et al., 2008). Another on aviremic and 
viremic patients with cryptogenic liver disease HCV-associated systemic vasculitis, or 
connective tissue disease detected HCV RNA only in the peripheral blood mononuclear 
cells of patients with viremic HCV RNA (Halfon et al., 2008). These results were obtained 
using appropriate sample processing and highly sensitive methods; they do not support 
the idea of HCV persistence. 
8.1.2 Improvement of liver histology after successful anti-HCV treatment 
The vast majority of patients achieving sustained virological response demonstrate 
histologic improvements on post-treatment liver biopsies relative to pretherapy (Pearlman 
and Traub, 2011). The fibrosis scores of 82-88% patients were improved and cirrhosis 
regressed in 64% of patients. Only a small percentage of liver specimens taken after an 
interferon-induced sustained virological response contained persistent HCV RNA. For 
example, only 7 (2%) of 400 sustained virologic responders had detectable HCV RNA in 
post-treatment liver biopsies (McHutchison et al., 2002). And two of them had a virological 
relapse 12 months following completion of treatment. Histological studies showed that 
reduced liver inflammation and improved fibrosis scores in patients with a chronic HCV 
infection and advanced fibrosis or cirrhosis often accompanies a histological improvement 
(Formann et al., 2006, George et al., 2009, Marcellin et al., 1997a). This supports the idea of 
HCV elimination.  
8.1.3 Few virological relapse in immunocompromised patients 
A few cases of HCV recurrence have been reported in immunocompromised patients, 
supporting the hypothesis of HCV persistence. One patient was reinfected by the same HCV 
genotype after chemotherapy for lymphoma (Thomopoulos et al., 2008). The re-emergence 
of HCV was described in a patient who had been given a short course of prednisolone seven 
months after the end of HCV therapy, and in another who underwent a kidney 
transplantation seven months after the end of HCV therapy (Lin et al., 2008). Studies on 
larger cohorts of patients with an impaired immune system due to HIV coinfection (Page et 
al., 2010) or immunosuppressive treatment following renal transplantation (Kamar et al., 
2003, Nicot et al., 2010) found no HCV RNA persisting in either the serum or peripheral 
blood mononuclear cells. If HCV really does persist, we should find a greater percentage of 
relapse in HIV coinfected patients and renal transplanted patients. These data point to the 
definitive elimination of HCV in patients with undetectable HCV RNA.  
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8.2 How explain disagreement between studies? 
The disagreement between reports of the definitive elimination of HCV or its persistence 
may be linked to differences in the criteria used to defined plasma viremia in apparently 
recovered patients. The standard techniques used to classify patients as sustained 
virological responders in studies describing occult HCV infections ranged from 50-600 
IU/mL (135 - 1000 copies/mL), whereas sensitive techniques with detection limits of < 50 
IU/mL have been recommended since 2002. About 60% of patients with an occult HCV 
infection had detectable HCV RNA in the plasma and their mean virus load was 71 HCV 
RNA copies/mL (range 18-192) (Bartolome et al., 2007). Therefore, HCV genomic RNA 
should have been detected by conventional tests if sensitive commercial RT-PCR methods 
had been used to screen the patients. This is supported by the demonstration that serum 
samples from 6.1% of 184 sustained virological responders that were HCV RNA negative 
with a standard PCR assay (detection limit 100 IU/mL) tested positive with the TMA assay 
(detection limit: 5 IU/mL) (Morishima et al., 2008). It is therefore important to use sensitive 
methods to determine the virological response after anti-HCV treatment.  
New HCV infection cannot be excluded in studies showing persistent HCV infections 
because detailed viral molecular analysis was not used. The patients in these studies were 
often infected by intravenous drug use or unknown routes and so possibly became re-
exposed to the same source of contamination. Most analyses were done on the conserved 
5’UTR region, which do not discriminate well subtypes. No accurate phylogeny was done 
on the NS5B or HVR1-E2 region of the HCV genome. It is therefore difficult to be sure that it 
was exactly the same virus that reappeared or to exclude re-infection with a common source 
and a similar virus. This must be borne in mind in studies describing late relapses. 
8.3 Kinetics of HCV RNA in cells under treatment 
Analysis of the kinetics of HCV RNA in compartments other than the plasma may help us to 
understand HCV replication and identify clinically significant patterns of response to 
treatment. The declines in the concentrations of HCV RNA in the peripheral blood 
mononuclear cells and plasma of patients treated with pegylated interferon and ribavirin 
were comparable during the initial 12 weeks of therapy (Pugnale et al., 2008). The decrease 
in HCV RNA in the peripheral blood mononuclear cells started as early as in plasma in 
many patients, while the kinetics in the two compartments differed markedly for some of 
them, hinting at compartment-specific HCV replication and response to treatment. HCV 
RNA was undetectable in the peripheral blood mononuclear cells in 0% of patients on day 0, 
in 5% on day 1, in 15% on day 4, in 23.6% on day 8, in 48.6% on day 22, in 58% on day 43, in 
73% on day 71, and in 81% on day 85. This progression reflects the overall decay of HCV 
RNA in these cells. The rapid loss of virus from peripheral blood mononuclear cells was 
associated with a sustained virological response. Another study explored the presence of 
HCV RNA in different cell subsets (CD4+, CD8+, NK and B cells) of 34 HIV-HCV coinfected 
patients (23 sustained virological responders and 11 relapsers) at the end of antiviral 
therapy (de Felipe et al., 2009). HCV RNA was detected in cell subsets of 9 patients: two 
who achieved a sustained virological response and 7 who relapsed. There is thus a 
significant association between the presence of HCV RNA in cell subsets at the end of 
treatment and viral relapse. In the light of the high proportion of HCV-infected cells in cases 
of occult HCV infection, it is rather surprising that no more cases of HCV relapse were 
observed in this population.  
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8.4 Immune control of residual HCV RNA? 
A recent study provides data that could resolve this controversy. It seems that low 
concentrations of HCV RNA reappear sporadically after successful therapy in a small 
proportion of patients and that this is associated with stimulation of the cellular immune 
response that controls HCV infection (Veerapu et al., 2011). The plasma and peripheral 
blood mononuclear cells of 117 patients who had recovered from an HCV infection (tested 
with Cobas Amplicor HCV test, limit of detection: 100 IU/mL or 270 copies/mL) were re-
tested for HCV RNA with a more sensitive method (detection limit: < 40 copies/mL). The 
plasma of none of the 19 spontaneously recovered patients contained detectable HCV RNA. 
The cells of one of them tested positive for HCV RNA. The intensity of the PCR band 
decreased in cells collected later until complete clearance of HCV RNA from the cell 
compartment by week 93. This suggests that the persistence of a low concentration of HCV 
RNA is not a common feature of spontaneous HCV clearance. Plasma samples of 15 of 98 
(15%) recovered treated patients tested positive for HCV RNA and the peripheral blood 
mononuclear cells of 3 of 76 patients tested were positive. All the samples obtained later 
tested negative. The time that had passed since the cessation of therapy differed between 
those patients with detectable HCV RNA and those without. HCV RNA was mostly 
detected in the first 8 years after the end of therapy. All later samples tested were HCV RNA 
negative. The HCV-specific T cell response was more vigorous at the HCV RNA-positive 
time points than at HCV RNA-negative ones. It triggered non-structural proteins, which are 
not part of the virus particle but are present only when the virus infects cells and virus RNA 
is translated into proteins. There could therefore be a correlation between an increased 
antiviral T-cell response and persistent low concentrations of virus, with the T-cell response 
stimulated by antigen from the newly translated HCV RNA. These data suggest that trace 
amounts of HCV RNA may persist for a limited but not indefinite time after successful 
therapy and may sporadically reappear in the circulation. The residual virus is perpetually 
kept in check by the immune response. This may be missed in standard clinical evaluations, 
which typically assess the presence of HCV RNA at a single time point 6 months after 
cessation of therapy. Moreover, this study shows that peripheral blood mononuclear cells 
are unlikely to be a long-lived reservoir of HCV in aviremic patients. 
9. Conclusion 
Most reports of HCV RNA sequences in cell or liver specimens despite HCV RNA being 
undetectable have come from a relatively few teams studying small cohorts of patients, but 
none of these patients experienced a real virological relapse. The clinical impact of low 
levels of HCV replication is not yet well defined. It is not clear whether these findings are 
replication-competent virus, have any clinical significance, or whether the situation 
predisposes to virus breakthrough. However, the majority of data from long-term follow-up 
studies on large cohorts of patients have failed to confirm occult HCV infection. Patients 
achieving a sustained virological response are very unlikely to suffer a relapse. Very few of 
them had detectable HCV RNA in their livers, the main replication site, and the liver 
histology of the majority of them improved. Further well-designed, multicenter, prospective 
trials are necessary for interferon-based therapies and also in the future for antiviral 
therapies based on specifically targeted antiviral therapy for HCV to finally resolved these 
conflicting data.  
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Waiting new results, we must therefore conclude that a sustained virological response 
should be considered to be a durable marker of virus eradication because there is limited 
evidence for occult HCV infection. The patients can be considered not infectious and cured 
from a virological standpoint. 
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